Ascent Wealth Partners LLC acquired a new stake in Pfizer Inc. (NYSE:PFE) in the 4th quarter, Holdings Channel reports. The institutional investor acquired 16,322 shares of the biopharmaceutical company’s stock, valued at approximately $712,000.

A number of other institutional investors and hedge funds have also modified their holdings of the business. OppenheimerFunds Inc. increased its stake in shares of Pfizer by 32.2% in the 3rd quarter. OppenheimerFunds Inc. now owns 6,890,372 shares of the biopharmaceutical company’s stock valued at $303,659,000 after buying an additional 1,678,438 shares during the period. Viridian Ria LLC increased its stake in shares of Pfizer by 0.9% in the 4th quarter. Viridian Ria LLC now owns 30,859 shares of the biopharmaceutical company’s stock valued at $1,327,000 after buying an additional 280 shares during the period. Rehmann Capital Advisory Group increased its stake in shares of Pfizer by 1.4% in the 3rd quarter. Rehmann Capital Advisory Group now owns 125,426 shares of the biopharmaceutical company’s stock valued at $5,528,000 after buying an additional 1,759 shares during the period. Focused Wealth Management Inc increased its stake in shares of Pfizer by 160.7% in the 3rd quarter. Focused Wealth Management Inc now owns 83,780 shares of the biopharmaceutical company’s stock valued at $3,692,000 after buying an additional 51,644 shares during the period. Finally, Cavalier Investments LLC acquired a new stake in shares of Pfizer in the 4th quarter valued at $1,176,000. Hedge funds and other institutional investors own 71.88% of the company’s stock.

In other Pfizer news, major shareholder Pfizer Inc bought 50,000 shares of the firm’s stock in a transaction on Monday, May 13th. The stock was purchased at an average cost of $17.00 per share, with a total value of $850,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Rady A. Johnson sold 8,700 shares of the business’s stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $41.13, for a total value of $357,831.00. Following the completion of the transaction, the insider now directly owns 59,797 shares of the company’s stock, valued at $2,459,450.61. The disclosure for this sale can be found here. 0.09% of the stock is owned by insiders.

Shares of Pfizer stock opened at $42.67 on Wednesday. The company has a quick ratio of 1.27, a current ratio of 1.54 and a debt-to-equity ratio of 0.60. Pfizer Inc. has a 12 month low of $35.73 and a 12 month high of $46.47. The firm has a market cap of $239.77 billion, a P/E ratio of 14.22, a P/E/G ratio of 2.48 and a beta of 0.64.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, April 30th. The biopharmaceutical company reported $0.85 EPS for the quarter, topping analysts’ consensus estimates of $0.75 by $0.10. Pfizer had a return on equity of 27.48% and a net margin of 21.31%. The business had revenue of $13.12 billion during the quarter, compared to analysts’ expectations of $13.01 billion. During the same period in the previous year, the firm earned $0.77 earnings per share. The firm’s quarterly revenue was up 1.6% compared to the same quarter last year. As a group, equities research analysts anticipate that Pfizer Inc. will post 2.89 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 7th. Investors of record on Friday, May 10th were paid a dividend of $0.36 per share. The ex-dividend date was Thursday, May 9th. This represents a $1.44 dividend on an annualized basis and a dividend yield of 3.37%. Pfizer’s dividend payout ratio (DPR) is presently 48.00%.

PFE has been the subject of several research reports. Bank of America lifted their target price on Pfizer from $45.00 to $48.00 and gave the company a “buy” rating in a research note on Monday, April 1st. Cantor Fitzgerald reissued a “buy” rating and issued a $53.00 target price on shares of Pfizer in a research note on Tuesday, February 19th. Credit Suisse Group reissued a “buy” rating and issued a $48.00 target price on shares of Pfizer in a research note on Monday, May 6th. Goldman Sachs Group initiated coverage on Pfizer in a research note on Tuesday, May 28th. They issued a “conviction-buy” rating for the company. Finally, Barclays reissued a “hold” rating and issued a $41.00 target price on shares of Pfizer in a research note on Thursday, May 9th. Thirteen analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. Pfizer presently has a consensus rating of “Hold” and an average target price of $46.00.

ILLEGAL ACTIVITY WARNING: This news story was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://theolympiareport.com/2019/06/12/ascent-wealth-partners-llc-acquires-shares-of-16322-pfizer-inc-nysepfe.html.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Read More: Asset Allocation

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.